Skip to main content

Treanda Side Effects

Generic name: bendamustine

Medically reviewed by Philip Thornton, DipPharm. Last updated on Jun 1, 2023.

Note: This document contains side effect information about bendamustine. Some dosage forms listed on this page may not apply to the brand name Treanda.

Applies to bendamustine: intravenous powder for solution, intravenous solution.

Serious side effects of Treanda

Along with its needed effects, bendamustine (the active ingredient contained in Treanda) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking bendamustine:

More common

Less common

Incidence not known

Other side effects of Treanda

Some side effects of bendamustine may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to bendamustine: intravenous powder for injection, intravenous solution.

Hematologic

Very common (10% or more): Decreased lymphocytes (up to 99%), decreased leukocytes (up to 94%), decreased hemoglobin (up to 89%), decreased neutrophils (up to 86%), decreased platelets (up to 86%), lymphocytopenia (up to 74%), neutropenia (up to 45%), thrombocytopenia (up to 39%), anemia (up to 38%), leukopenia (up to 37%)

Common (1% to 10%): Febrile neutropenia, hemorrhage, lymphopenia

Very rare (less than 0.01%): Hemolysis

Postmarketing reports: Pancytopenia[Ref]

Gastrointestinal

Very common (10% or more): Nausea (up to 77%), diarrhea (up to 42%), vomiting (up to 40%), constipation (up to 31%), stomatitis (up to 21%), abdominal pain (up to 14%), dyspepsia (up to 14%), gastroesophageal reflux disease (up to 11%)

Common (1% to 10%): Dry mouth, upper abdominal pain, abdominal distension, oral candidiasis

Very rare (less than 0.01%): Gastrointestinal hemorrhage, hemorrhagic esophagitis[Ref]

Other

Very common (10% or more): Fatigue (up to 64%), infectious episodes (up to 37%), pyrexia (up to 36%), chills (up to 14%), asthenia (up to 13%), herpes zoster (up to 12%), mucosal inflammation

Common (1% to 10%): Pain, infection, herpes simplex, amenorrhea, epididymitis, thirst, cytomegalovirus infection

Uncommon (0.1% to 1%): Sepsis

Very rare (less than 0.01%): Infertility, multi-organ failure

Frequency not reported: Septic shock, general physical health deterioration

Postmarketing reports: Progressive multifocal leukoencephalopathy[Ref]

Hepatic

Very common (10% or more): Elevated bilirubin (up to 34%), increased creatinine, increased urea

Common (1% to 10%): Increased AST, increased ALT, increased alkaline phosphatase

Frequency not reported: Hepatitis, hepatic failure, gallbladder pain[Ref]

Metabolic

Very common (10% or more): Anorexia (up to 24%), decreased weight (up to 20%), dehydration (up to 15%), decreased appetite (up to 13%), hypokalemia (up to 11%)

Common (1% to 10%): Hyperuricemia, tumor lysis syndrome, hypomagnesemia[Ref]

Respiratory

Very common (10% or more): Cough (up to 22%), dyspnea (up to 17%), upper respiratory tract infection (up to 10%), pharyngolaryngeal pain (up to 10%)

Common (1% to 10%): Nasopharyngitis, sinusitis, pneumonia, wheezing, nasal congestion, pulmonary dysfunction

Very rare (less than 0.01%): Pulmonary fibrosis

Frequency not reported: Lung neoplasm, lung infiltration, pleural effusion

Postmarketing reports: Pneumocystis jiroveci pneumonia, pneumonitis[Ref]

Nervous system

Very common (10% or more): Headache (up to 21%), dizziness (up to 15%), dysgeusia (up to 11%)

Rare (less than 0.1%): Somnolence, aphonia

Very rare (less than 0.01%): Paresthesia, peripheral sensory neuropathy, anticholinergic syndrome, neurological disorders, ataxia, encephalitis

Frequency not reported: Paraplegia, neuralgia[Ref]

Dermatologic

Very common (10% or more): Rash (up to 16%), erythema (up to 16%), skin allergic reactions (up to 15%)

Common (1% to 10%): Pruritus, dry skin, night sweats, hyperhidrosis, alopecia, skin disorders

Rare (less than 0.1%): Dermatitis, macular-papular rash

Frequency not reported: Toxic skin reactions, bullous exanthema, urticaria

Postmarketing reports: Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS), non-melanoma skin cancer (NMSC), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN)[Ref]

Psychiatric

Very common (10% or more): Insomnia (up to 15%)

Common (1% to 10%): Anxiety, depression[Ref]

Cardiovascular

Very common (10% or more): Peripheral edema (up to 14%)

Common (1% to 10%): Tachycardia, chest pain, hypotension, cardiac dysfunction (palpitations, angina pectoris, arrhythmia), hypertension

Uncommon (0.1% to 1%): Pericardial effusion

Rare (less than 0.1%): Myocardial infarction, acute circulatory failure, cardiac failure

Very rare (less than 0.01%): Phlebitis

Frequency not reported: Vasculitis

Postmarketing reports: Atrial fibrillation, congestive heart failure[Ref]

Musculoskeletal

Very common (10% or more): Back pain (up to 14%)

Common (1% to 10%): Arthralgia, extremity pain, bone pain, myalgia

Frequency not reported: Sacral pain[Ref]

Genitourinary

Very common (10% or more): Urinary tract infection (up to 11%)[Ref]

Hypersensitivity

Common (1% to 10%): Hypersensitivity reactions

Rare (less than 0.1%): Anaphylaxis, anaphylactoid reaction

Very rare (less than 0.01%): Anaphylactic shock[Ref]

Local

Common (1% to 10%): Infusion site pain, catheter site pain

Frequency not reported: Extravasation injury, infusion reactions, injection site reactions[Ref]

Ocular

Frequency not reported: Retinal detachment[Ref]

Oncologic

Frequency not reported: Pre-malignant and malignant diseases/secondary tumors[Ref]

Renal

Frequency not reported: Acute renal failure[Ref]

Frequently asked questions

References

1. Cerner Multum, Inc. UK Summary of Product Characteristics.

2. Cerner Multum, Inc. Australian Product Information.

3. Product Information. Treanda (bendamustine). Cephalon Inc. 2008.

4. Product Information. Bendeka (bendamustine). Teva Pharmaceuticals USA. 2016.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.